- Home
- Automated
- List of product information
- GANFORT EYE DROPS [SIN13589P]
GANFORT EYE DROPS [SIN13589P]
Active ingredients: GANFORT EYE DROPS
Last updated 26 October 2025
Product Info
GANFORT EYE DROPS
[SIN13589P]
Product information
Active Ingredient and Strength | BIMATOPROST - 0.3 MG/ML |
Dosage Form | SOLUTION, STERILE |
Manufacturer and Country | ALLERGAN PHARMACEUTICALS IRELAND - IRELAND |
Registration Number | SIN13589P |
Licence Holder | ABBVIE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | S01ED51 |
INDICATIONS AND USAGE
Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
DOSAGE AND ADMINISTRATION
Recommended dosage in adults (including the elderly)
The recommended dose is one drop of GANFORT® in the affected eye(s) once daily, administered either in the morning or in the evening. It should be administered at the same time each day.
Existing literature data for GANFORT® suggest that evening dosing may be more effective in IOP lowering than morning dosing. However, consideration should be given to the likelihood of compliance when considering either morning or evening dosing.
If one dose is missed, treatment should continue with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.
If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart.
Use in renal and hepatic impairment
GANFORT® has not been studied in patients with hepatic or renal impairment. Therefore caution should be used in treating such patients.
Use in children and adolescents
GANFORT® has only been studied in adults and therefore its use is not recommended in children or adolescents.
CONTRAINDICATIONS
Hypersensitivity to the active substances or to any of the excipients.
Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease.
Sinus bradycardia, sick sinus syndrome, sino-atrial nodal block, second or third degree atrioventricular block not controlled with a pacemaker; overt cardiac failure, cardiogenic shock.